Cargando…
Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion
Bevacizumab is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the management of macular edema in central retinal vein occlusion (CRVO). Studying retinal protein changes in bevacizumab intervention may provide insights into mechanisms of action. In nine Danish Landrace pi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672637/ https://www.ncbi.nlm.nih.gov/pubmed/38003895 http://dx.doi.org/10.3390/jpm13111580 |
_version_ | 1785140438068363264 |
---|---|
author | Cehofski, Lasse Jørgensen Kruse, Anders Mæng, Mads Odgaard Kjaergaard, Benedict Grauslund, Jakob Honoré, Bent Vorum, Henrik |
author_facet | Cehofski, Lasse Jørgensen Kruse, Anders Mæng, Mads Odgaard Kjaergaard, Benedict Grauslund, Jakob Honoré, Bent Vorum, Henrik |
author_sort | Cehofski, Lasse Jørgensen |
collection | PubMed |
description | Bevacizumab is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the management of macular edema in central retinal vein occlusion (CRVO). Studying retinal protein changes in bevacizumab intervention may provide insights into mechanisms of action. In nine Danish Landrace pigs, experimental CRVO was induced in both eyes with argon laser. The right eyes received an intravitreal injection of 0.05 mL bevacizumab (n = 9), while the left control eyes received 0.05 mL saline water (NaCl). Retinal samples were collected 15 days after induced CRVO. Label-free quantification nano-liquid chromatography–tandem mass spectrometry identified 59 proteins that were regulated following bevacizumab treatment. Following bevacizumab intervention, altered levels of bevacizumab components, including the Ig gamma-1 chain C region and the Ig kappa chain C region, were observed. Changes in other significantly regulated proteins ranged between 0.58–1.73, including for the NADH-ubiquinone oxidoreductase chain (fold change = 1.73), protein-transport protein Sec24B (fold change = 1.71), glycerol kinase (fold change = 1.61), guanine-nucleotide-binding protein G(T) subunit-gamma-T1 (fold change = 0.67), and prefoldin subunit 6 (fold change = 0.58). A high retinal concentration of bevacizumab was achieved within 15 days. Changes in the additional proteins were limited, suggesting a narrow mechanism of action. |
format | Online Article Text |
id | pubmed-10672637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106726372023-11-07 Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion Cehofski, Lasse Jørgensen Kruse, Anders Mæng, Mads Odgaard Kjaergaard, Benedict Grauslund, Jakob Honoré, Bent Vorum, Henrik J Pers Med Article Bevacizumab is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the management of macular edema in central retinal vein occlusion (CRVO). Studying retinal protein changes in bevacizumab intervention may provide insights into mechanisms of action. In nine Danish Landrace pigs, experimental CRVO was induced in both eyes with argon laser. The right eyes received an intravitreal injection of 0.05 mL bevacizumab (n = 9), while the left control eyes received 0.05 mL saline water (NaCl). Retinal samples were collected 15 days after induced CRVO. Label-free quantification nano-liquid chromatography–tandem mass spectrometry identified 59 proteins that were regulated following bevacizumab treatment. Following bevacizumab intervention, altered levels of bevacizumab components, including the Ig gamma-1 chain C region and the Ig kappa chain C region, were observed. Changes in other significantly regulated proteins ranged between 0.58–1.73, including for the NADH-ubiquinone oxidoreductase chain (fold change = 1.73), protein-transport protein Sec24B (fold change = 1.71), glycerol kinase (fold change = 1.61), guanine-nucleotide-binding protein G(T) subunit-gamma-T1 (fold change = 0.67), and prefoldin subunit 6 (fold change = 0.58). A high retinal concentration of bevacizumab was achieved within 15 days. Changes in the additional proteins were limited, suggesting a narrow mechanism of action. MDPI 2023-11-07 /pmc/articles/PMC10672637/ /pubmed/38003895 http://dx.doi.org/10.3390/jpm13111580 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cehofski, Lasse Jørgensen Kruse, Anders Mæng, Mads Odgaard Kjaergaard, Benedict Grauslund, Jakob Honoré, Bent Vorum, Henrik Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion |
title | Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion |
title_full | Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion |
title_fullStr | Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion |
title_full_unstemmed | Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion |
title_short | Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion |
title_sort | proteome analysis of bevacizumab intervention in experimental central retinal vein occlusion |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672637/ https://www.ncbi.nlm.nih.gov/pubmed/38003895 http://dx.doi.org/10.3390/jpm13111580 |
work_keys_str_mv | AT cehofskilassejørgensen proteomeanalysisofbevacizumabinterventioninexperimentalcentralretinalveinocclusion AT kruseanders proteomeanalysisofbevacizumabinterventioninexperimentalcentralretinalveinocclusion AT mængmadsodgaard proteomeanalysisofbevacizumabinterventioninexperimentalcentralretinalveinocclusion AT kjaergaardbenedict proteomeanalysisofbevacizumabinterventioninexperimentalcentralretinalveinocclusion AT grauslundjakob proteomeanalysisofbevacizumabinterventioninexperimentalcentralretinalveinocclusion AT honorebent proteomeanalysisofbevacizumabinterventioninexperimentalcentralretinalveinocclusion AT vorumhenrik proteomeanalysisofbevacizumabinterventioninexperimentalcentralretinalveinocclusion |